Seqone
Bioinformatics · Genomics & Genetic Testing
Overview
SeqOne is the all-in-one genomic analysis platform trusted by 140+ labs worldwide. Speed up insights, ensure clinical-grade accuracy, and personalize your genomic workflows.
Funding and backers
Team
11-50
employees, estimated range
Backers
2
Omnes Capital, Supernova Invest
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Tractionpublic signals, read monthly
Web presence
top 8%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Discover WhiteLab Genomics, where AI meets biology to revolutionize genomic medicine. Our innovative platform optimizes drug design for…
MicroPure's vision is to eliminate front-end bottlenecks, unlocking genomic analysis anytime, anywhere, by anyone About MicroPure Genomics…
MedGenome is a genomics diagnostics and research company that applies machine learning to South Asian genetic data. Founded in 2013 in…
Phase Genomics: Fueling Genomic Discovery. CytoTerra® Cytogenetics, ProxiMeta™ Metagenome Deconvolution, Proximo™ Genome Scaffolding.
ChromaCode is a leading provider of HDPCR™ multiplexing technology for genomic solutions. Our breakthrough platform enables labs…
Actionable Genomic Evidence at the Gene & Variant Level Aligned with ACMG/AMP. Supporting Patient Diagnosis & Precision Medicine for Rare…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Supernova InvestVia a fund
Omnes CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
SeqOne Acquires Congenica Forming Global Leader in AI-powered Genomic Medicines PharmExec
SeqOne
Read more
Report
READ THE FULL ARTICLE
Methods: The study comprised 368 patients from the PAOLA-1 trial. The SeqOne assay was compared to the Myriad MyChoice HRD test (Myriad Genetics), and results were analyzed with respect to Progression-Free Survival (PFS).
Read more
Report
SeqOne Genomics: SeqOne's New Clinically Validated HRD Test Reduces Number of Inconclusive Results to Improve the Prescription of Targeted Treatments for Ovarian Cancer Patients
The Homologous Recombination Deficiency (HRD) biomarker identifies ovarian cancer patients likely to respond to PARP-inhibitors. SeqOne's test simplifies the deployment of this test while
Read more
Report
SeqOne's New Clinically Validated HRD Test Reduces Number of Inconclusive Results to Improve the Prescription of Targeted Treatments for Ovarian Cancer Patients
Read more
Report
SeqOne's New Clinically Validated HRD Test Reduces Number of Inconclusive Results to Improve the Prescription of Targeted Treatments for Ovarian Cancer Patients
Business Wire Press Release.
Read more
Report
SeqOne Genomics, French CNR-MAT pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times
SeqOne Genomics, French CNR-MAT pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times
Read more
Report
SeqOne Genomics Closes €20M Series a to Accelerate the Deployment of Its Genomic Medicine Platform
The funding will drive international deployment of the company's next generation genomic analysis platform to enable personalized medicine in cancers as well as rare and hereditary diseases. SeqOne
Read more
Report